Skip to Main content
  • This site is for U.S. residents only
  • Full Prescribing Information
  • Important Risk Information
  • Patient Medication Guide
  • HEALTHCARE PROFESSIONALS
  • VIBERZI® (eluxadoline) is a prescription medicine used to treat adults who have irritable bowel syndrome with diarrhea (IBS-D).
Viberzi® (eluxadoline) tablets CIV 75 mg, 100 mg logo

This site is for U.S. residents only

  • About IBS-D
  • About VIBERZI
  • Patient Resources
  • Savings Program
  • Healthcare Professional Site
Savings Program

Doctor Guide

SITE MAP

  • Home
  • About IBS-D
  • About VIBERZI
  • Patient Resources
  • Savings Program
  • Prescribing Information
  • Healthcare Professional Site
  • Privacy Notice
  • Terms of Use
  • Contact Us

IMPORTANT RISK INFORMATION

USE

What is VIBERZI?

VIBERZI® (eluxadoline) is a prescription medicine used to treat adults who have irritable bowel syndrome with diarrhea (IBS-D).

IMPORTANT RISK INFORMATION

VIBERZI can cause serious side effects, including:

  • Inflammation of the pancreas (pancreatitis) has happened most often in people who do not have a gallbladder and can lead to hospitalization. Pancreatitis has led to death in some people who do not have a gallbladder. Pancreatitis usually happens within the first week of treatment with VIBERZI, but can happen after 1 to 2 doses of VIBERZI. Your risk of getting pancreatitis is increased if you drink more than 3 alcoholic drinks a day. Limit your use of alcoholic drinks while you are taking VIBERZI.
  • A spasm in a muscle of the digestive system (called the sphincter of Oddi), which may cause new or worsening abdominal pain. Sphincter of Oddi spasm has happened most often in people who do not have a gallbladder and can lead to hospitalization. This spasm usually happens within the first week of treatment, but can happen after 1 to 2 doses of VIBERZI.

Stop taking VIBERZI right away and get emergency medical care if you have new or worsening stomach-area (abdomen) pain or pain in the upper right side of your stomach-area (abdomen) that may move to your back or shoulder, with or without nausea and vomiting.

  • Serious allergic reactions have happened in some people after taking 1 or 2 doses of VIBERZI. Stop taking VIBERZI right away and get emergency medical care if you have signs or symptoms of an allergic reaction, including: swelling of your face, lips, mouth or tongue; shortness of breath or other breathing problems; itching, rash, or hives.
  • Constipation, including severe constipation that can lead to hospitalization, has happened after taking VIBERZI. Stop taking VIBERZI and call your doctor right away if you develop severe constipation while taking VIBERZI.

Do not take VIBERZI if you:

  • Do not have a gallbladder
  • Have or may have had a blockage in your gallbladder or a sphincter of Oddi problem
  • Have or had problems with alcohol abuse, alcohol addiction, or drink more than 3 alcoholic drinks a day
  • Have had pancreatitis or other pancreas problems, including if you have had or may have had a blockage in your pancreas
  • Have had an allergic reaction to VIBERZI
  • Have severe liver problems
  • Have had long-lasting (chronic) or severe constipation, or problems caused by constipation
  • Have or may have had a bowel blockage (intestinal obstruction)

Before taking VIBERZI, tell your doctor about all of your medical conditions, including if you have liver problems, are pregnant or plan to become pregnant, are breastfeeding or plan to breastfeed.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. If you are taking VIBERZI you should not take medicines that cause constipation, including Lotronex® (alosetron), anticholinergic medicines, and opioid pain medicines.

The most common side effects of VIBERZI include constipation, nausea, and abdominal pain. Stop taking VIBERZI and call your doctor if you have constipation that is severe. These are not all the possible side effects of VIBERZI. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call
1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.

For further information, please talk to your healthcare professional.

US-VBZ-230025

  • Home
  • Site Map
  • Accessibility Statement
  • Contact Us
  • Terms of Use
  • Privacy Notice
  • Cookie settings
  • Your Privacy Choices
AbbVie logo

VIBERZI® and its design are registered trademarks of Allergan Holdings Unlimited Company, an AbbVie company.
© 2024 AbbVie. All rights reserved.

The product information provided on this site is intended only for residents of the United States.

The products discussed on this site may have different product labeling outside of the United States.

The health information described on this site is for educational purposes only and is not intended to substitute for discussions with a healthcare provider.

US-VBZ-230063

Viberzi logo

You are now leaving VIBERZI.COM consumer site

You are about to enter a site that is for U.S. Healthcare Professionals only. By selecting "Yes" below, you certify that you are a Healthcare Professional and that you wish to proceed to the Healthcare Professionals Only section of this site. Products or treatments described on this site are available in the U.S. but may not be available in all other countries.

I am a licensed Healthcare Professional and wish to proceed to the Healthcare Professionals Only section of this site.

NO
YES

US-VBZ-230063

You are now leaving VIBERZI.COM

A link to a non-AbbVie website does not constitute an endorsement of the product or services offered by the non-AbbVie website, nor is AbbVie responsible for the content of any non-AbbVie website.

Would you like to continue?

CANCEL
CONTINUE

US-VBZ-230063

Program Terms, Conditions, and Eligibility Criteria

This offer is valid only for patients with commercial prescription insurance coverage, who are 18 years of age or older and meet eligibility criteria and is good for use only with a valid prescription for VIBERZI® (eluxadoline) 75 mg or 100 mg tablets at the time the prescription is filled by the pharmacist and dispensed to the patient. This offer is not valid for use by patients enrolled in Medicare, Medicaid, or other federal or state programs (including any state pharmaceutical assistance programs, TRICARE, Department of Defense or Veterans Affairs programs), or private indemnity or HMO insurance plans that reimburse you for the entire cost of your prescription drugs, or where prohibited by law or by the patient’s health insurance provider. Patients may not use this card if they are Medicare-eligible and enrolled in an employer-sponsored health plan or prescription drug benefit program for retirees. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be eligible to use the VIBERZI Savings Card. This offer is not valid for cash-paying patients. Offer good only in the USA, including Puerto Rico, at participating retail pharmacies. Void if prohibited by law, taxed, or restricted. Patients residing in or receiving treatment in certain states may not be eligible to participate in this program. Depending on your insurance coverage, most eligible patients may pay as little as $30 per 30-day, 60-day, or 90-day supply for each of up to twelve (12) prescription fills per calendar year. This offer is valid for up to
twelve (12) prescription fills. AbbVie reserves the right to rescind, revoke, or amend this offer without notice. Patients may not seek reimbursement for value received under the VIBERZI Savings Card program from any third-party payers. This offer is not transferable. The selling, purchasing, trading, or counterfeiting of this card is prohibited by law. This offer has no cash value and may not be used in combination with any other discount, coupon, rebate, free trial, or similar offer for the specified prescription. Subject to all other terms and conditions, the maximum annual benefit that may be available solely for the patient’s benefit under the co-pay assistance program is $13,714.00 per calendar year. The actual application and use of the benefit available under the co-pay assistance program may vary on a monthly, quarterly, and/or annual basis depending on each individual patient’s plan of insurance and other prescription drug costs. This offer is not health insurance. By redeeming this card, you acknowledge that you are an eligible patient and that you understand and agree to comply with the terms and conditions of this offer. To learn about AbbVie’s privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy.

US-VBZ-230063

You are now leaving VIBERZI.COM

A link to a non-AbbVie website does not constitute an endorsement of the product or services offered by the non-AbbVie website, nor is AbbVie responsible for the content of any non-AbbVie website.

Would you like to continue?

CANCEL
CONTINUE

US-VBZ-230063

IMPORTANT RISK INFORMATION

USE

What is VIBERZI?

VIBERZI® (eluxadoline) is a prescription medicine used to treat adults who have irritable bowel syndrome with diarrhea (IBS-D).

IMPORTANT RISK INFORMATION

VIBERZI can cause serious side effects, including:

  • Inflammation of the pancreas (pancreatitis) has happened most often in people who do not have a gallbladder and can lead to hospitalization. Pancreatitis has led to death in some people who do not have a gallbladder. Pancreatitis usually happens within the first week of treatment with VIBERZI, but can happen after 1 to 2 doses of VIBERZI. Your risk of getting pancreatitis is increased if you drink more than 3 alcoholic drinks a day. Limit your use of alcoholic drinks while you are taking VIBERZI.

IMPORTANT RISK INFORMATION

VIBERZI can cause serious side effects, including:

  • Inflammation of the pancreas (pancreatitis) has happened most often in people who do not have a gallbladder and can lead to hospitalization. Pancreatitis has led to death in some people who do not have a gallbladder.

IMPORTANT RISK INFORMATION

VIBERZI can cause serious side effects, including:

  • Inflammation of the pancreas (pancreatitis) has happened most often in people who do not have a gallbladder and can lead to hospitalization. Pancreatitis has led to death in some people who do not have a gallbladder. Pancreatitis usually happens within the first week of treatment with VIBERZI, but can happen after 1 to 2 doses of VIBERZI. Your risk of getting pancreatitis is increased if you drink more than 3 alcoholic drinks a day. Limit your use of alcoholic drinks while you are taking VIBERZI.

IMPORTANT RISK INFORMATION

USE

What is VIBERZI?

VIBERZI® (eluxadoline) is a prescription medicine used to treat adults who have irritable bowel syndrome with diarrhea (IBS-D).

IMPORTANT RISK INFORMATION

VIBERZI can cause serious side effects, including:

  • Inflammation of the pancreas (pancreatitis) has happened most often in people who do not have a gallbladder and can lead to hospitalization. Pancreatitis has led to death in some people who do not have a gallbladder. Pancreatitis usually happens within the first week of treatment with VIBERZI, but can happen after 1 to 2 doses of VIBERZI. Your risk of getting pancreatitis is increased if you drink more than 3 alcoholic drinks a day. Limit your use of alcoholic drinks while you are taking VIBERZI.

IMPORTANT RISK INFORMATION

VIBERZI can cause serious side effects, including:

  • Inflammation of the pancreas (pancreatitis) has happened most often in people who do not have a gallbladder and can lead to hospitalization. Pancreatitis has led to death in some people who do not have a gallbladder.

IMPORTANT RISK INFORMATION

VIBERZI can cause serious side effects, including:

  • Inflammation of the pancreas (pancreatitis) has happened most often in people who do not have a gallbladder and can lead to hospitalization. Pancreatitis has led to death in some people who do not have a gallbladder. Pancreatitis usually happens within the first week of treatment with VIBERZI, but can happen after 1 to 2 doses of VIBERZI. Your risk of getting pancreatitis is increased if you drink more than 3 alcoholic drinks a day. Limit your use of alcoholic drinks while you are taking VIBERZI.

IMPORTANT RISK INFORMATION

USE

What is VIBERZI?

VIBERZI® (eluxadoline) is a prescription medicine used to treat adults who have irritable bowel syndrome with diarrhea (IBS-D).

IMPORTANT RISK INFORMATION

VIBERZI can cause serious side effects, including:

  • Inflammation of the pancreas (pancreatitis) has happened most often in people who do not have a gallbladder and can lead to hospitalization. Pancreatitis has led to death in some people who do not have a gallbladder. Pancreatitis usually happens within the first week of treatment with VIBERZI, but can happen after 1 to 2 doses of VIBERZI. Your risk of getting pancreatitis is increased if you drink more than 3 alcoholic drinks a day. Limit your use of alcoholic drinks while you are taking VIBERZI.
  • A spasm in a muscle of the digestive system (called the sphincter of Oddi), which may cause new or worsening abdominal pain. Sphincter of Oddi spasm has happened most often in people who do not have a gallbladder and can lead to hospitalization. This spasm usually happens within the first week of treatment, but can happen after 1 to 2 doses of VIBERZI.

Stop taking VIBERZI right away and get emergency medical care if you have new or worsening stomach-area (abdomen) pain or pain in the upper right side of your stomach-area (abdomen) that may move to your back or shoulder, with or without nausea and vomiting.

  • Serious allergic reactions have happened in some people after taking 1 or 2 doses of VIBERZI. Stop taking VIBERZI right away and get emergency medical care if you have signs or symptoms of an allergic reaction, including: swelling of your face, lips, mouth or tongue; shortness of breath or other breathing problems; itching, rash, or hives.
  • Constipation, including severe constipation that can lead to hospitalization, has happened after taking VIBERZI. Stop taking VIBERZI and call your doctor right away if you develop severe constipation while taking VIBERZI.

Do not take VIBERZI if you:

  • Do not have a gallbladder
  • Have or may have had a blockage in your gallbladder or a sphincter of Oddi problem
  • Have or had problems with alcohol abuse, alcohol addiction, or drink more than 3 alcoholic drinks a day
  • Have had pancreatitis or other pancreas problems, including if you have had or may have had a blockage in your pancreas
  • Have had an allergic reaction to VIBERZI
  • Have severe liver problems
  • Have had long-lasting (chronic) or severe constipation, or problems caused by constipation
  • Have or may have had a bowel blockage (intestinal obstruction)

Before taking VIBERZI, tell your doctor about all of your medical conditions, including if you have liver problems, are pregnant or plan to become pregnant, are breastfeeding or plan to breastfeed.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. If you are taking VIBERZI you should not take medicines that cause constipation, including Lotronex® (alosetron), anticholinergic medicines, and opioid pain medicines.

The most common side effects of VIBERZI include constipation, nausea, and abdominal pain. Stop taking VIBERZI and call your doctor if you have constipation that is severe. These are not all the possible side effects of VIBERZI. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call
1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.

For further information, please talk to your healthcare professional.

US-VBZ-230025